Sphingolipids in Asthma Pathogenesis

Not yet recruiting

• Conditions: Asthma

• Registration Number: NCT06539221
• Lead Sponsor: Peking University Third Hospital

Brief Summary

The study aims to investigate the relationship between the small molecule metabolite sphingolipids and asthma clinical features and explore its involvement in asthma pathogenesis.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2024-07
• Study First Submitted: 2024-08-01
• Study First Submitted QC: 2024-08-01
• Last Update Submitted: 2024-08-01
• Study First Posted: 2024-08-06
• Last Update Posted: 2024-08-06
• Study Start: 2024-09-01
• Primary Completion: 2025-09-01
• Study Completion: 2026-09-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• 1. clinical diagnosis of asthma

Read More

Exclusion Criteria

• 1. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor 2. Combined with acute and chronic respiratory failure 3. Combined with severe cardiovascular disease 4. Pregnant woman.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
lipidomics	Day 1	collect blood for lipidomic analysis and in vitro assays

Trial Locations

Locations (1)

Peking university third hospital; 🇨🇳 Beijing, Beijing, China